Skip to main content
. 2018 Jan 19;9(11):9808–9824. doi: 10.18632/oncotarget.24275

Figure 7. RRD-251 promotes D3-induced regulation of GSK-3 expression and inhibitory phosphorylation.

Figure 7

Changes in total expression and the specific inhibitory phosphorylation of GSK-3 α/β were assessed by Western blotting. 25 μg of protein from cytoplasmic and nuclear lysates collected 48 hours after treatment were resolved on 12% polyacrylamide gels. (A-B) Total cytoplasmic expression of GSK-3 α/β are unchanged with D3 or co-treatment. (C-D) D3 promotes cytoplasmic serine 21/9 (inhibitory) phosphorylation of GSK-3 α/β. Co-treatment with RRD-251 enhances the D3-induced phosphorylation of serine 21/9. (E-F) Nuclear expression of GSK-3 α/β decreases after D3 treatment, with further reductions in expression with RRD-251 co-treatment. (G-H) D3 promotes nuclear serine 21/9 (inhibitory) phosphorylation of GSK-3 α/β. Co-treatment with RRD-251 enhances the D3-induced phosphorylation of serine 21/9.